This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Understand what constitutes a good asset allocation for beginners. Enhance your investment strategy with proven insights.
17,719 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A wave of selling in software names is prompting a rethinking of where capital flows. Market insiders say the episode...
A concentrated bet from a top consumer-focused fund puts Chime in the spotlight. Discover what the $227 million posit...
Palantir often looks pricey at first glance, but the real story may be hidden in growth engines and future contracts....
As 2026 unfolds, oil markets face three potential paths. This guide breaks down the scenarios and offers concrete ste...
AI optimism pushed valuations to lofty highs. This guide explains why stocks wall street says to be cautious about tw...
Apple faces a window of opportunity as upbeat quarterly results and expanding services/supporting growth drivers push...
Centene's Sarah London, the youngest-ever female Fortune 500 CEO, is steering a bold reinvention of the nation's larg...
A headline about Palantir and a high-stakes defense AI plan could reshape risk and opportunity. This guide breaks dow...
A 20-year-old data analyst managing two jobs, a new gym venture with $80,000 in debt, and a newborn faces a burnout c...
The White House extended the deadline for Iran to reopen the Strait of Hormuz to April 6, sparking a fresh wave of oi...
Investors are weighing how legal rulings against Meta could reshape risk and earnings. This guide breaks down what ha...